Genextra Spa:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Genextra Spa - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10890
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Genextra SpA (Genextra) is a therapies developing company that discovers and develops therapies for age-related and metabolic diseases. The company develops INT-747 for comb, INT- 777 for metabolic syndrome, mono therapy and diabetes, novel HDAC and HSP90 inhibitors for the treatment of cancer. It also provides mjPTP inhibitor and nanoparticles in gas phase to yields, among others. Genextra provides research in life science and to develop novel therapies and tools, among others. The company caters to entrepreneurs and financial institutions in partnership with leading scientists, among others. It operates through its subsidiaries located across Italy. Genextra is headquartered in Milan, Italy.

Genextra Spa – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genextra Spa, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Genextra Spa, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Genextra Spa, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
EryDel Raises USD32.4 Million in Venture Financing 10
EryDel Raises Additional USD16.23 million in Series B Financing 11
EryDel Raises US$20 Million In Series B Financing 12
Intercept Pharma Raises US$30 Million In Series C Financing 13
Partnerships 15
Intercept Pharma Extends Agreement with Target Pharma 15
Intercept Pharma Enters into Research Agreement with University of Perugia 16
Licensing Agreements 17
EryDel and Orphan Technologies Enter into Licensing Agreement 17
Equity Offering 18
Intercept Pharma Prices Private Placement of Shares for USD100 Million 18
Intercept Pharma Prices Public Offering of Shares for USD150 Million 20
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 22
Intercept Pharma Raises USD202 Million in Public Offering of Shares 24
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 26
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 28
Intercept Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$86 Million 30
Debt Offering 32
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 32
Genextra Spa – Key Competitors 34
Genextra Spa – Key Employees 35
Genextra Spa – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Genextra Spa, Pharmaceuticals & Healthcare, Key Facts 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genextra Spa, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genextra Spa, Deals By Therapy Area, 2012 to YTD 2018 8
Genextra Spa, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
EryDel Raises USD32.4 Million in Venture Financing 10
EryDel Raises Additional USD16.23 million in Series B Financing 11
EryDel Raises US$20 Million In Series B Financing 12
Intercept Pharma Raises US$30 Million In Series C Financing 13
Intercept Pharma Extends Agreement with Target Pharma 15
Intercept Pharma Enters into Research Agreement with University of Perugia 16
EryDel and Orphan Technologies Enter into Licensing Agreement 17
Intercept Pharma Prices Private Placement of Shares for USD100 Million 18
Intercept Pharma Prices Public Offering of Shares for USD150 Million 20
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 22
Intercept Pharma Raises USD202 Million in Public Offering of Shares 24
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 26
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 28
Intercept Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$86 Million 30
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 32
Genextra Spa, Key Competitors 34
Genextra Spa, Key Employees 35
Genextra Spa, Subsidiaries 36

List of Figures
Genextra Spa, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genextra Spa, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Genextra Spa:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AnaptysBio Inc (ANAB):製薬・医療:M&Aディール及び事業提携情報
    Summary AnaptysBio Inc (AnaptysBio) is a clinical-stage biotechnology company that focuses on the development of antibody product candidates for the treatment of inflammatory, autoimmune and atopic diseases. The company develops its product candidates through its proprietary antibody discovery techn …
  • Avaya Inc.:戦略・SWOT・企業財務分析
    Avaya Inc. - Strategy, SWOT and Corporate Finance Report Summary Avaya Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Panhandle Oil and Gas Inc. (PHX)-石油・ガス分野:企業M&A・提携分析
    Summary Panhandle Oil and Gas Inc. (Panhandle) is an upstream oil and gas company that carries out exploration, development, production and sale of oil and natural gas. It is involved in the acquisition, management and development of non-operated oil and natural gas properties, including wells locat …
  • YGM Trading Ltd.:戦略・SWOT・企業財務分析
    YGM Trading Ltd. - Strategy, SWOT and Corporate Finance Report Summary YGM Trading Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Williams Partners LP:企業のM&A・事業提携・投資動向
    Williams Partners LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Williams Partners LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Gardiner & Theobald LLP:企業の戦略的SWOT分析
    Gardiner & Theobald LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Step Pharma SAS-製薬・医療分野:企業M&A・提携分析
    Summary Step Pharma SAS (Step Pharma) is a biotechnology company, which strives to discover and develop proprietary small molecule medicines for the treatment of auto-immune diseases. The company is developing a new class of oral nucleotide synthesis inhibitors against cytidine triphosphate synthase …
  • Liechtensteinische Landesbank AG:企業の戦略・SWOT・財務情報
    Liechtensteinische Landesbank AG - Strategy, SWOT and Corporate Finance Report Summary Liechtensteinische Landesbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Impact Developer & Contractor SA:企業の戦略・SWOT・財務情報
    Impact Developer & Contractor SA - Strategy, SWOT and Corporate Finance Report Summary Impact Developer & Contractor SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • TransForce Inc.:企業のM&A・事業提携・投資動向
    TransForce Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's TransForce Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Spectra Energy Partners LP (SEP):石油・ガス:M&Aディール及び事業提携情報
    Summary Spectra Energy Partners LP (Spectra Energy), a subsidiary of Enbridge Inc., is a master limited partnership operating in mid-stream energy. The company conducts transmission, storage and gathering of natural gas. It also carries out the transportation and storage of crude oil. Spectra Energy …
  • WGL Holdings Inc (WGL)-石油・ガス分野:企業M&A・提携分析
    Summary WGL Holdings, Inc. (WGL) is an energy holding company that delivers natural gas, and provides energy-related products and services to customers. It also provides design-build energy efficient and sustainable solutions and water and energy-related infrastructure services. The company delivers …
  • Ping An Insurance (Group) Company of China, Ltd.:企業のM&A・事業提携・投資動向
    Ping An Insurance (Group) Company of China, Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ping An Insurance (Group) Company of China, Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business descri …
  • Desjardins Financial Security Life Assurance Company:企業の戦略・SWOT・財務情報
    Desjardins Financial Security Life Assurance Company - Strategy, SWOT and Corporate Finance Report Summary Desjardins Financial Security Life Assurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's st …
  • Naturgy Energy Group SA. (NTGY):石油・ガス:M&Aディール及び事業提携情報
    Summary Naturgy Energy Group SA (Naturgy) formerly know as Gas Natural Fenosa, is an integrated gas and electric utility that carries out the exploration, development, liquefaction, regasification, transportation, storage, distribution and commercialization of natural gas. It also undertakes the gen …
  • Itochu Techno-Solutions Corp (4739):企業の財務・戦略的SWOT分析
    Itochu Techno-Solutions Corp (4739) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Hydro-Electric Corporation:企業の戦略的SWOT分析
    Hydro-Electric Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Wake Forest Innovations-製薬・医療分野:企業M&A・提携分析
    Summary Wake Forest Innovations (Wake Forest), a subsidiary of Wake Forest Baptist Medical Center, is an enterprise that advances the development and commercialization of discoveries; services; and products such as medicines and vaccines, from the Medical Center and Wake Forest University. The compa …
  • Luminex Corp (LMNX):医療機器:M&Aディール及び事業提携情報
    Summary Luminex Corp (Luminex) is a medical devices company which develops, manufactures and markets proprietary biological testing technologies. The company offers wide range of products including instruments, assays, reagents and accessories, software and replacement parts. Its proprietary technol …
  • Hindustan Construction Co. Ltd (HCC):企業の財務・戦略的SWOT分析
    Hindustan Construction Co. Ltd (HCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆